化合物MF-438 | 921605-87-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 化合物MF-438
• 英文名称: MF-438
• 英文别名: 2-methyl-5-(6-(4-(2-(trifluoromethyl) phenoxy)piperidin1-yl)pyridazin-3-yl)-1,3,4-thiadiazole；2-Methyl-5-(6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)pyridazin-3-yl)-1,3,4-thiadiazole；2-methyl-5-[6-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]pyridazin-3-yl]-1,3,4-thiadiazole
• CAS: 921605-87-0
• 化学式: C₁₉H₁₈F₃N₅OS
• 分子量: 421.446
• InChiKey: NVUJDKDVOZVALT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  92.3
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  N'-acetyl-6-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}pyridazine-3-carbohydrazide 在 phosphorous (V) sulfide 作用下， 以 xylene 为溶剂， 反应 16.0h， 生成 化合物MF-438
  参考文献：
  名称：

  WO2007/9236

  摘要：

  公开号：

文献信息

• Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
  申请人：Black Cameron

  公开号：US20090118296A1

  公开（公告）日：2009-05-07

  Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and fatty liver disease.

  结构式（I）的杂环芳香化合物是选择性的硬脂酰辅酶A-Δ9-脱饱和酶（SCD1）抑制剂，相对于其他已知的硬脂酰辅酶A脱饱和酶。本发明的化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病、动脉粥样硬化、脂质代谢紊乱、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗和脂肪肝病。
• Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)
  作者：Serge Léger、W. Cameron Black、Denis Deschenes、Sarah Dolman、Jean-Pierre Falgueyret、Marc Gagnon、Sébastien Guiral、Zheng Huang、Jocelyne Guay、Yves Leblanc、Chun-Sing Li、Frédéric Massé、Renata Oballa、Lei Zhang

  DOI：10.1016/j.bmcl.2009.11.111

  日期：2010.1

  A series of stearoyl-CoA desaturase 1 (SCD1) inhibitors were developed. Investigations of enzyme potency and metabolism led to the identification of the thiadiazole-pyridazine derivative MF-438 as a potent SCD1 inhibitor. MF-438 exhibits good pharmacokinetics and metabolic stability, thereby serving as a valuable tool for further understanding the role of SCD inhibition in biological and pharmacological models of diseases related to metabolic disorders. (C) 2009 Elsevier Ltd. All rights reserved.
• SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

  公开号：EP2852387A2

  公开（公告）日：2015-04-01
• EXPRESSION CONTROL USING A REGULATABLE INTRON
  申请人：Synpromics Limited

  公开号：EP3673068A1

  公开（公告）日：2020-07-01
• COMPOUNDS AND METHODS FOR TREATING CANCER
  申请人：Mayo Foundation for Medical Education and Research

  公开号：US20190345123A1

  公开（公告）日：2019-11-14

  This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.